Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial ☆
Titel:
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial ☆
Auteur:
Siefker-Radtke, A.O. Matsubara, N. Park, S.H. Huddart, R.A. Burgess, E.F. Özgüroğlu, M. Valderrama, B.P. Laguerre, B. Basso, U. Triantos, S. Akapame, S. Kean, Y. Deprince, K. Mukhopadhyay, S. Loriot, Y.